DEF 14A: Precision BioSciences Sets Date for 2024 Annual Stockholders Meeting, Outlines Key Proposals

Precision BioSciences announces its 2024 annual meeting of stockholders to be held virtually on June 4, 2024, outlining proposals for director elections, auditor ratification, incentive plan amendments, and potential meeting adjournment.

Summary

• Precision BioSciences will hold its 2024 annual meeting of stockholders on June 4, 2024, at 11:00 a.m. Eastern Time, as a virtual meeting.
• Stockholders of record as of April 8, 2024, are entitled to vote.
• The meeting will address the election of Stanley R. Frankel, M.D. and Samuel Wadsworth, Ph.D. as Class II directors, ratification of Deloitte & Touche LLP as the independent registered public accounting firm for 2024, approval of the amendment and restatement of the Company's 2019 Incentive Award Plan, and approval of a potential adjournment to solicit additional proxies for Proposal No. 3.
• The Board recommends voting 'FOR' all proposals.
• The company is requesting stockholders approve an increase of 630,000 shares to the 2019 Incentive Award Plan.
• As of April 18, 2024, the company had 5,633 shares remaining for future grant under the 2019 Plan.
• The company's three-year average net burn rate is 3.7%.
• If approved, the proposal to add 630,000 shares would result in an overhang of 15.9% for the 2019 Plan.
• The Board of Directors unanimously recommends a vote FOR the election of each of Dr. Stanley Frankel and Dr. Samuel Wadsworth as a Class II director to hold office until the 2027 Annual Meeting and until his respective successor has been duly elected and qualified.
• The Board of Directors unanimously recommends a vote FOR the ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The Board of Directors unanimously recommends a vote FOR the approval of an amendment and restatement of the 2019 Plan.
• The Board of Directors unanimously recommends a vote FOR the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal No. 3.

Sentiment

Score: 7

Explanation: The document is primarily informational, outlining the proposals for the annual meeting. The board's recommendations are positive, and the company's equity grant practices are described as responsible. However, the limited number of shares remaining for future grants and the underwater stock options are potential concerns.

Positives

• The company is committed to good corporate governance practices by seeking stockholder ratification of the auditor appointment.
• The company's historical equity grant practices are responsible, with a three-year average net burn rate of 3.7%, aligned with market norms.
• The proposed share increase for the 2019 Incentive Award Plan is intended to retain and motivate talent, aligning employee interests with long-term stockholder value.
• The 2019 Plan contains equity compensation best practices, including broad-based eligibility, director award limits, and no repricing of awards without stockholder approval.

Negatives

• The company has a limited number of shares remaining for future grants under the 2019 Plan (5,633 shares as of April 18, 2024), which could hinder its ability to attract and retain talent if the proposal is not approved.
• All stock options granted under the 2019 Plan are underwater with a weighted average exercise price of $180.15 per share.

Risks

• Failure to approve the amendment and restatement of the 2019 Incentive Award Plan could limit the company's ability to attract, retain, and motivate employees.
• If the company cannot deliver equity compensation, there is significant risk associated with an inability to deliver equity compensation.
• If there are not sufficient votes at the time of the Annual Meeting to approve Proposal No. 3, the company may need to adjourn the Annual Meeting to solicit additional proxies.

Future Outlook

The company aims to continue using the 2019 Plan to achieve its performance, recruiting, retention, and incentive goals, which are considered essential to its success.

Management Comments

• The Board believes that approval of the amendment and restatement of the 2019 Plan is in the best interests of the Company and the Board recommends that stockholders vote for approval of this Proposal No. 3.

Industry Context

The document references an analysis of 161 biotechnology companies with market capitalizations between $50-300 million to benchmark Precision BioSciences' equity grant practices.

Comparison to Industry Standards

• The company's three-year average net burn rate of 3.7% is aligned with the median of market data for similarly situated companies.
• The proposed overhang of 15.9% for the 2019 Plan is consistent with historical levels and aligned with the median of market data for similarly situated companies.

Stakeholder Impact

• Approval of the incentive plan amendment is intended to benefit employees by providing equity compensation opportunities.
• Stockholders will be impacted by the decisions made regarding director elections, auditor ratification, and the incentive plan amendment.
• The company's ability to attract and retain talent will be affected by the outcome of the vote on the incentive plan amendment.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold its annual meeting on June 4, 2024, to address the outlined proposals.

Key Dates

Keywords

annual meeting, proxy statement, stockholders, incentive plan, director election, Deloitte & Touche, executive compensation, corporate governance, equity awards, Precision BioSciences